go to site Kudos to Dr. Oz for urging viewers NOT to buy into the idea that injections of human growth hormone are the fountain of youth. My favorite quote: “It is not worth risking your health for the pursuit of youth and beauty.”
Archive for the ‘HGH’ Category
I was interviewed about my book on TalkRadio 630, Denver, on a show called “The Caring Generation.” The show was appropriately called “Fear of Aging and American Values.” Host Pamela Wilson asked me mostly about human growth hormone (HGH)–what’s been proven, what hasn’t, and why some doctors are determined to prescribe HGH as the fountain of youth.
In 1990, a scientist at the Medical College of Wisconsin named Daniel Rudman published a study that gave birth to the modern anti-aging movement. Rudman’s paper, which was published in the New England Journal of Medicine showed that 12 men who were given injections of human growth hormone (HGH) lost 14 percent of their body fat and increased their lean body mass — including muscle — by 9 percent. HGH, which is mostly used to help short children grow, became the go-to drug for perfectly healthy, aging people who were in search of the fountain of youth.
Now, one of Rudman’s closest friends is throwing cold water on the theory that HGH should be embraced as an anti-aging elixir. Read more here.
On September 14, the United States District Court for the District of Massachusetts issued a ruling that effectively ended a whistleblower’s attempts to bring attention to the off-label marketing of human growth hormone for anti-aging and other non-approved uses. Former Pfizer executive Peter Rost filed the qui tam claim in 2003, and I wrote about it in Selling the Fountain of Youth. In short, Rost alleged that Pfizer improperly promoted its HGH drug Genotropin by providing kickbacks to physicians, including all-expense-paid trips to medical conferences in exotic locations.
Rost wasn’t exactly Mr. Popular at Pfizer. After he filed his qui tam, the company started dismantling his 60-person team, moving everybody but Rost from their New Jersey office to New York City. Then men in hardhats showed up and started knocking down the walls around him. Rost ultimately lost his job.
In 2005, the U.S. Dept. of Justice declined to join Rost in his suit and instead investigated Pfizer on its own. Two years later, in a settlement with the government, Pfizer paid a fine of $15 million and admitted that the unit that made Genotropin, Pharmacia, had promoted it for off-label uses such as anti-aging. (The company paid an additional $19.7 million fine related to a separate charge.) In an online posting, Rost dismissed the settlement as “equivalent to a speeding ticket”–a reference to the fact that Pfizer’s profit the previous year had been $11 billion.
Rost continued to fight his whistleblower claim, but it was a struggle. In 2008, a judge ruled that he could proceed as long as he focused only on allegations related to the promotion of HGH for the treatment of short children. His dream of exposing off-label use of HGH in anti-aging clinics was dead.
And now this latest ruling. It states that Rost failed to show that Pfizer’s promotion of HGH violated the False Claims Act. In other words, those activities did not result in improper claims being made to state Medicaid programs, as Rost alleged in his amended complaint. The ruling was made partially on the judge’s determination that the pharmacies that filled the prescriptions were “third parties” who were not knowledgeable about the marketing of the drug. If the pharmacy does not know that the prescription was written because a doctor was induced by the drugmaker to write it, she said, then there is no illegal false claim.
Jim Edwards, a blogger for BNET who mentioned my book in his posting about the case, concluded that this ruling “has made it easier for drug companies to bribe doctors with cash and gifts to prescribe their products.” I’m not sure I would go that far. But I will say this: Rost’s long and dramatic whistleblower story has come to a rather deflating end.
With a mixture of shock and amazement, I read a story in today’s New York Times called “Am I Young Yet?” It was written by Elizabeth Hayt, who at the age of 48, began injecting herself with human growth hormone (HGH), one of the anti-aging industry’s drugs of choice.
Hayt tried HGH because she thought it might help speed up her recovery from ankle surgery. But she admitted she was also drawn to it because an anti-aging doctor told her “HGH should also help you lose weight, and you’ll love the way it will make your skin look younger.”
In reality, it appeared that HGH turned Hayt’s face into a disaster area. She ended up with 5 moles, 25 enlarged oil glands and 50 angiofibromas–small pocks around her nose.
Many scientists believe that HGH, true to its name, makes things grow–and often not pleasant things. In Selling the Fountain of Youth, I recount the story of Hanneke Hops, a northern California woman who told the San Francisco Chronicle in 2003 that daily injections of HGH were making her strong and healthy enough to run marathons, ride horses, and fly planes. Three months later she died from cancer, her liver riddled with tumors. Her son suspected a link to HGH.
It’s difficult to prove scientifically that HGH causes dangerous side effects, or worse, cancer. But there have been plenty of anecdotal reports–such as those of Hayt and Hops–that suggest patients should proceed with extreme caution. At least they should ask themselves: Is the quest for youth worth the risks?